Who
Vimal Mehta
CEO and President
Company insider
Files Form 4 as: CEO and President, BioXcel Therapeutics.
In numbers
- Trades disclosed
- 146
- Buys
- 9
- Sells
- 13
- Bought
- $89K
- Sold
- $18.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Mar 2018
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —219 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —219 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —219 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —219 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K19,419 at $1.09 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K19,419 at $1.09 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —49,758 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,758 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,758 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —49,758 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —18,000 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —18,000 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —219 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —219 at $0.00 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —219 at $0.00 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —219 | filing |
| 14 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —164 | filing |
| 14 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —164 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.